CBD is the major non-psychotropic cannabinoid found in Hemp. It is the principal cannabinoid present in fiber-type Hemp (in the form of its carboxylic acid CBDA), a plant that is easily available to researchers, in contrast to the strictly controlled drug-type Hemp varieties. Second to THC, the pharmacological effects of CBD have been best studied of all cannabinoids. It has notable anti-inflammatory and immunomodulatory effects. Furthermore, sedating, hypnotic, anti-epileptic, and antidystonic effects have been described. Also, CBD is a modulator of some types of opioid-receptors, and can modulate sleep. The German Extract Method results in a high CBD product that tests lower than .3% THC.
Controls certain cancers, eases pain, stimulates bone growth, stops growth of bacteria, suppresses muscle spasms and convulsions, slows inflammation, reduces blood sugar levels, reduces the risk of artery obstructions, decreases pressure in the blood vessel walls, helps control epileptic seizures, reduces risk of nerve damage, eases nausea.
Hemp contains at least 60 known chemicals called cannabinoids, which activate naturally occurring cannabinoid receptors in your body.
Tetrahydrocannabinol, or THC, is the main component responsible for the psychoactive effects, or “high,” hemp is known for. While THC is known to have some medicinal value, there has been recent investigation into a new cannabinoid that is said to have more medicinal benefits than any single pharmaceutical drug on the market.
This cannabinoid is known as Cannabidiol (CBD), and is the second most abundant cannabinoid in hemp. Research done by G.W. Pharmaceuticals suggests that CBD could be used for treating symptoms of rheumatoid arthritis and other autoimmune diseases, diabetes, nausea, bowel disorders, and many other hard-to-control side effects. According to an article from Projectcbd.com, CBD has even demonstrated neuroprotective effects, and its anti-cancer potential is currently being explored. While it was originally believed that THC is a breakdown product of CBD, it is now known that both THC and CBD are actually metabolites of their decarboxylated acidic forms, THCa and CBDa. These acidic precursors are decarboxylated (essentially dried) by heat or extraction to produce THC and CBD; only then do they become psychoactive. The compound has medicinal benefits without the “high” that some patients do not desire. This makes CBD appealing to patients who are looking for an alternative to their current meds, which often have opiate-like effects.
Cannabidiol is even known to counteract some of the effects of THC like the “munchies.” Just as THC increases our appetite, CBD suppresses it, which could be ideal for patients watching their figure. CBD just might be a key ingredient in a future weight loss drug, who knows? There is one exception to the theory that CBD suppresses appetite, but it is a blessing as well. Many people who have difficulty eating due to their stress or anxiety can use CBD to get rid of that sick feeling in their chest or stomach, allowing them to eat again once their anxiety subsides. A recent study published in The International Journal of Neurophamacology points to Cannabidiol (CBD) as a cause of Neurogenesis in the brain; specifically in the Hippocampus, an area typically associated with conscious memory and navigation. However, the researchers believe that CBD’s anxiety relief may be due to this neurogenesis in the brain.
Cannabidiol is what gives hemp its sedative effect, and has been known to ease a number of symptoms from difficult conditions. There has actually been a substantial amount of experiments done on cannabidiol that has proved its healing powers. Dr. Sean McAllister, a scientist from the Pacific Medical Center in San Francisco, made an astounding discovery about CBD. McAllister has been studying cannabinoid compounds for 10 years now in search of new therapeutic interventions for various cancers. He discovered that cannabidiol is a potent inhibitor of cancer cell proliferation, metastasis, and tumor growth. Results of his experiments on breast cancer show that the number of cancer cells diminished as more CBD was applied. Essentially, CBD may be a generally effective way to switch off the cancer-causing gene, providing patients with a non-toxic therapy to treat aggressive forms of cancer.
Raphael Mechoulam of the Hebrew University, Jerusalem, and Faculty of Medicine has been studying cannabinoids for almost 50 years. Mechoulam gave a talk on cannabidiol on the 45th year of involvement in the field in which he spoke about a number of experiments being done on cannabidiol. He described an experiment that was done in Brazil in which a 200mg/day dosage of CBD was added to the anticonvulsants epilepsy patients were currently taking. Over the course of several months only 1 of the 7 patients showed no improvement; three became seizure-free; one experienced only one or two seizures, and two experienced reduced severity and occurrence of seizures.
A colleague of Mechoulam’s, Marc Feldman at Imperial College, London, tested CBD on mice that had a version of rheumatoid arthritis. He found that CBD reduced the mice’s inflammation by 50% at the right dosage. Cardiologists working with the mice at Hebrew University have found that a dosage of CBD immediately following a heart attack can reduce infarct size by about 66%.
Another notable study conducted by Mechoulam was done on mice bred to have a version of type-1 diabetes. The diabetes was designed to manifest right around 14 weeks, so the mice were treated with CBD for the first 7 weeks of their life and then again in another 7 weeks. He concluded that only 30% had developed diabetes compared to the 90-100% given the placebo. He then repeated the experiment where the CBD wasn’t introduced until 14 weeks when the diabetes first developed. They were then tested at 24 weeks of age and again only 30% of the treated mice were found to have diabetes. “CBD did not just prevent onset,” said Mechoulam, “it blocked the development of diabetes.”